A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2+ Metastatic Breast Cancer (MBC)
Interventions: DRUG: neratinib|DRUG: capecitabine|DRUG: lapatinib
Sponsor: Puma Biotechnology, Inc.